PTC Therapeutics (PTCT) stock price, revenue, and financials

PTC Therapeutics market cap is $2.8 b, and annual revenue was $380.77 m in FY 2020
View Company

$2.8 B

PTCT Mkt cap, 12-Nov-2021

$380.8 M

PTC Therapeutics Revenue FY, 2020
PTC Therapeutics Net income (FY, 2020)-438.2 M
PTC Therapeutics EBIT (FY, 2020)-431.8 M
PTC Therapeutics Cash, 31-Dec-2020208.8 M
PTC Therapeutics EV3 B
Get notified regarding key financial metrics and revenue changes at PTC TherapeuticsLearn more
Banner background

PTC Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

34.7m25.2m36.8m82.7m194.4m264.7m307.0m380.8m

Revenue growth, %

(27%)46%125%

Cost of goods sold

4.6m12.7m12.1m

Gross profit

189.8m252.1m294.8m

Gross profit Margin, %

98%95%96%

R&D expense

54.9m79.8m121.8m117.6m117.5m172.0m257.5m477.6m

General and administrative expense

25.2m44.8m82.1m97.1m121.3m153.5m202.5m245.2m

Operating expense total

80.1m124.7m203.9m214.8m254.1m367.7m536.0m722.8m

Depreciation and amortization

15.4m22.9m

EBIT

(45.4m)(99.4m)(167.1m)(132.1m)(64.3m)(115.7m)(241.2m)(431.8m)

EBIT margin, %

(131%)(394%)(455%)(160%)(33%)(44%)(79%)(113%)

Interest expense

6.1m1.2m2.4m8.3m12.1m12.6m12.5m56.4m

Pre tax profit

(51.6m)(98.4m)(170.0m)(141.5m)(77.7m)(128.1m)(239.9m)(402.9m)

Income tax expense

(4.7m)485.0k569.0k1.3m(29.0k)11.7m35.2m

Net Income

(51.6m)(93.8m)(170.4m)(142.1m)(79.0m)(128.1m)(251.6m)(438.2m)

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

6.9m16.3m9.2m1.7m1.7m7.5m6.8m9.8m18.9m15.6m23.0m26.5m48.0m41.9m56.1m68.7m53.6m53.6m85.5m71.4m68.3m75.2m118.4m

Cost of goods sold

39.0k758.0k1.6m3.0m2.6m3.3m2.4m3.2m3.0m

Gross profit

26.5m47.2m40.3m53.0m66.2m50.3m51.2m82.3m68.4m

Gross profit Margin, %

100%98%96%95%96%94%96%96%96%

R&D expense

14.7m13.9m15.9m18.3m18.8m27.9m28.2m30.6m31.4m28.8m31.4m27.4m30.8m30.0m31.4m32.6m54.4m52.6m60.0m63.1m90.1m93.0m

General and administrative expense

6.6m6.7m7.5m8.7m10.5m17.6m17.2m21.4m25.9m23.4m23.7m25.5m28.9m31.4m33.0m33.5m38.4m40.5m49.2m49.3m58.2m57.8m

Operating expense total

21.3m20.6m23.4m27.0m29.3m45.6m45.4m52.0m57.3m52.2m55.1m52.9m59.7m71.2m69.8m71.7m98.5m120.3m121.1m128.9m148.3m150.8m

Depreciation and amortization

9.7m5.4m5.6m5.8m7.0m7.9m9.6m

EBIT

(14.5m)(4.3m)(14.2m)(25.4m)(27.6m)(38.1m)(38.6m)(42.2m)(38.4m)(36.6m)(32.1m)(26.4m)(12.5m)(30.9m)(16.7m)(5.6m)(48.2m)(69.1m)(38.8m)(60.5m)(93.0m)(55.1m)

EBIT margin, %

(211%)(26%)(154%)(1513%)(1629%)(509%)(570%)(432%)(203%)(234%)(139%)(99%)(26%)(74%)(30%)(8%)(90%)(129%)(45%)(85%)(136%)(47%)

Interest expense

114.2k26.7k171.0k248.0k354.0k524.0k498.0k852.0k2.0m2.1m2.1m2.2m3.0m3.4m3.3m2.9m3.1m2.3m2.1m2.7m5.6m21.0m

Pre tax profit

(38.2m)(43.1m)(41.1m)(39.0m)(35.0m)(28.9m)(17.3m)(33.5m)(19.0m)(9.1m)(50.6m)(71.5m)(41.0m)(60.3m)(112.5m)(47.4m)

Income tax expense

145.0k88.0k114.0k(93.0k)184.0k165.0k150.0k191.0k221.0k389.0k355.0k(576.0k)774.0k(344.0k)222.0k22.3m

Net Income

(14.6m)(4.4m)(14.1m)(25.1m)(27.3m)(37.9m)(38.4m)(43.2m)(41.2m)(38.9m)(35.2m)(29.1m)(17.5m)(33.7m)(19.3m)(9.5m)(51.0m)(72.1m)(41.8m)(60.0m)(112.7m)(69.7m)

PTC Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

15.4m49.7m58.0m58.3m111.8m169.5m288.0m208.8m

Accounts Receivable

4.4m11.1m24.9m40.4m67.9m55.5m69.9m

Prepaid Expenses

1.6m3.9m5.9m6.7m9.2m17.9m39.5m

Inventories

4.7m10.8m16.1m19.3m18.7m

Current Assets

145.0m323.6m355.9m261.3m249.1m320.9m779.3m1.2b

PP&E

6.7m9.2m9.0m8.4m12.7m21.5m33.8m

Goodwill

82.3m82.3m82.3m

Total Assets

151.9m333.2m368.0m269.3m391.7m1.1b1.6b2.2b

Accounts Payable

1.1m4.1m11.9m48.8m15.3m6.0m10.3m18.7m

Short-term debt

48.6k11.7m20.0m7.5m

Current Liabilities

13.1m32.5m45.4m49.6m82.0m166.8m235.9m277.3m

Long-term debt

94.6m98.2m145.0m141.3m293.9m411.7m

Total Debt

48.6k94.6m98.2m145.0m153.0m313.9m419.2m

Total Liabilities

15.4m34.8m142.0m149.8m235.2m768.5m1.0b1.7b

Common Stock

24.3k33.0k34.0k42.0k51.0k62.0k70.0k

Additional Paid-in Capital

465.2m721.7m820.2m856.1m966.5m1.3b1.8b2.2b

Retained Earnings

(328.8m)(422.6m)(593.0m)(735.1m)(814.1m)(938.9m)(1.2b)(1.6b)

Total Equity

136.5m298.5m226.0m119.6m156.4m350.7m594.3m482.0m

Debt to Equity Ratio

0 x0.4 x0.8 x0.9 x0.4 x

Debt to Assets Ratio

0 x0.3 x0.4 x0.4 x0.1 x

Financial Leverage

1.1 x1.1 x1.6 x2.3 x2.5 x3.2 x2.7 x4.6 x

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

154.1m24.0m115.9m21.2m52.9m36.8m29.2m140.7m40.2m35.7m50.3m54.1m133.0m141.8m97.7m223.8m206.9m201.1m136.1m523.6m123.3m158.5m434.0m

Accounts Receivable

1.3m3.2m5.1m8.0m22.6m19.8m27.4m32.2m33.8m38.7m45.6m59.4m42.2m46.4m77.1m60.4m52.6m53.6m56.8m

Prepaid Expenses

1.6m2.1m2.0m2.6m2.8m6.1m4.2m4.6m5.1m4.8m4.9m4.6m5.2m5.4m5.8m6.3m8.0m9.3m17.4m20.7m24.3m34.1m26.9m

Inventories

1.4m6.9m7.8m12.4m13.9m13.7m16.2m16.9m17.1m19.1m18.4m19.5m

Current Assets

168.2m160.1m249.4m230.3m213.5m289.8m264.6m384.2m326.4m297.4m280.6m240.7m227.0m221.3m242.0m375.6m313.3m479.1m475.0m806.9m691.9m605.0m1.2b

PP&E

7.2m6.9m6.3m6.4m6.2m9.4m9.0m8.8m8.4m7.6m7.1m7.1m6.8m6.9m8.3m8.2m8.8m14.5m15.4m18.5m26.2m26.8m28.1m

Goodwill

100.3m82.3m82.3m82.3m82.3m

Total Assets

175.5m167.2m255.8m237.6m220.8m299.5m273.8m396.1m335.2m305.6m288.2m248.6m383.1m367.7m379.4m511.8m1.0b1.3b1.3b1.6b1.5b1.5b2.2b

Accounts Payable

425.4k1.0m387.0k613.0k518.0k3.1m3.4m8.7m16.0m16.8m19.2m3.6m6.1m6.0m3.1m4.4m6.5m9.8m10.2m9.0m16.1m15.5m15.7m

Short-term debt

2.7m84.2k12.0k1.7m6.7m16.7m20.0m20.0m20.0m23.2m5.9m

Current Liabilities

19.8m13.9m9.2m11.6m17.3m23.9m23.1m31.7m43.9m42.9m48.9m45.4m68.0m71.9m72.7m86.5m114.9m143.0m174.0m183.5m217.7m201.8m253.8m

Long-term debt

93.2m93.4m94.9m96.6m99.9m141.2m143.1m146.9m147.2m144.3m147.2m144.1m302.6m294.6m319.1m407.3m

Total Debt

2.7m84.2k12.0k93.2m93.4m94.9m96.6m99.9m141.2m143.1m146.9m148.9m150.9m155.1m164.1m322.6m314.6m342.3m413.1m

Total Liabilities

22.5m16.2m11.5m13.8m19.5m26.2m25.2m126.9m139.2m139.9m148.0m147.8m213.3m221.8m229.1m244.4m642.5m771.0m802.9m977.8m1.0b904.1m1.7b

Common Stock

24.3k24.3k30.0k30.0k30.0k33.0k34.0k34.0k34.0k34.0k34.0k34.0k41.0k41.0k42.0k47.0k51.0k58.0k58.0k61.0k62.0k67.0k68.0k

Additional Paid-in Capital

459.4m462.0m587.1m591.6m596.6m734.5m747.9m812.3m829.1m837.9m847.7m865.8m949.3m958.2m975.4m1.1b1.3b1.5b1.5b1.8b1.8b2.1b2.1b

Retained Earnings

(306.5m)(310.9m)(342.9m)(368.0m)(395.3m)(460.5m)(498.8m)(542.0m)(634.2m)(673.1m)(708.3m)(764.2m)(781.6m)(815.4m)(830.1m)(839.6m)(890.6m)(1.0b)(1.1b)(1.1b)(1.3b)(1.5b)(1.6b)

Total Equity

152.9m151.0m244.3m223.8m201.3m273.3m248.6m269.2m196.0m165.6m756.0k(876.0k)2.0m3.0m150.3m267.4m386.1m512.9m488.7m663.7m528.7m572.5m511.0m

Debt to Equity Ratio

0 x0 x0.3 x0.5 x0.6 x127.7 x-114 x70.7 x47.5 x1 x0.6 x0.4 x0.3 x

Debt to Assets Ratio

0 x0 x0.2 x0.3 x0.3 x0.3 x0.4 x0.4 x0.4 x0.4 x0.3 x0.1 x0.1 x

Financial Leverage

1.1 x1.1 x1 x1.1 x1.1 x1.1 x1.1 x1.5 x1.7 x1.8 x381.2 x-283.8 x191.6 x122 x2.5 x1.9 x2.7 x2.5 x2.6 x2.5 x2.9 x2.6 x4.3 x

PTC Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(51.6m)(93.8m)(170.4m)(142.1m)(79.0m)(128.1m)(251.6m)(438.2m)

Depreciation and Amortization

2.4m2.2m2.9m3.3m17.7m26.1m32.2m43.5m

Accounts Receivable

56.1k(3.5m)(6.9m)(14.8m)(12.2m)(29.6m)11.5m(10.5m)

Inventories

(6.5m)(5.8m)(3.5m)1.8m

Accounts Payable

5.2m16.9m17.0m4.3m24.0m43.9m26.8m70.8m

Cash From Operating Activities

(46.9m)(57.3m)(124.3m)(103.6m)(10.1m)(27.6m)(98.6m)(194.1m)

Purchases of PP&E

(845.7k)(4.7m)(2.7m)(1.8m)(3.1m)(7.1m)(13.8m)(17.8m)

Cash From Investing Activities

(127.8m)(145.2m)(20.8m)104.5m13.1m(42.6m)(387.2m)(561.5m)

Long-term Borrowings

(5.0m)(49.0k)(46.2m)

Cash From Financing Activities

187.4m237.1m154.1m968.0k44.2m131.6m613.2m668.7m

Net Change in Cash

12.7m34.3m8.3m299.0k53.5m57.7m126.0m(79.2m)

Interest Paid

367.1k1.0k4.5m6.3m7.8m7.7m9.8m

Income Taxes Paid

2.1k111.0k943.0k1.1m1.6m2.1m26.4m

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(29.3m)(33.7m)(14.1m)(39.2m)(66.5m)(37.9m)(76.3m)(119.5m)(41.2m)(80.1m)(115.3m)(29.1m)(46.5m)(80.3m)(19.3m)(28.8m)(79.8m)(72.1m)(113.9m)(173.9m)(112.7m)(294.1m)(363.8m)

Depreciation and Amortization

1.2m1.8m588.0k1.2m1.7m634.0k1.3m2.1m849.0k1.7m2.5m612.0k1.4m11.7m6.0m12.2m19.3m7.1m14.8m22.9m9.2m19.4m31.1m

Accounts Receivable

143.2k230.0k120.0k100.0k(338.0k)1.3m(669.0k)(3.6m)(10.7m)(8.5m)(16.0m)(6.7m)(6.8m)(11.0m)(4.2m)(20.4m)(2.7m)20.8m(9.7m)5.9m2.3m1.9m121.0k

Inventories

(1.3m)(2.8m)(3.6m)(1.4m)(3.4m)(3.3m)(334.0k)(852.0k)(1.6m)102.0k943.0k390.0k

Accounts Payable

3.0m3.2m(3.5m)(866.0k)4.3m(5.6m)(6.0m)2.9m(2.5m)(3.4m)2.1m(3.9m)12.5m11.8m(6.8m)2.2m18.6m(28.7m)(7.5m)695.0k(4.0m)(7.5m)54.4m

Cash From Operating Activities

(27.3m)(32.5m)(13.4m)(32.2m)(49.3m)(36.4m)(66.2m)(94.0m)(41.6m)(66.2m)(90.2m)(28.9m)(15.6m)(31.4m)(15.9m)(15.9m)(12.5m)(42.4m)(72.9m)(88.4m)(81.6m)(156.4m)(129.7m)

Purchases of PP&E

(95.8k)(473.8k)(186.0k)(837.0k)(1.2m)(883.0k)(1.2m)(1.8m)(265.0k)(275.0k)(540.0k)(225.0k)(579.0k)(1.1m)(479.0k)(1.2m)(2.5m)(2.9m)(4.9m)(9.1m)(6.0m)(8.2m)(11.5m)

Cash From Investing Activities

(11.7m)(133.7m)(4.3m)(80.4m)(32.0m)20.6m37.3m31.0m22.1m43.1m81.4m24.4m47.9m67.2m(1.6m)6.1m(18.0m)(150.5m)(188.7m)(158.2m)(101.3m)40.8m(353.4m)

Long-term Borrowings

(2.2m)(5.0m)(37.0k)(49.0k)(49.0k)(5.0m)(25.0m)(46.2m)

Cash From Financing Activities

190.3m187.5m118.1m118.4m118.7m3.0m8.1m154.0m34.0k34.0k926.0k663.0k40.7m42.4m1.1m122.8m127.8m225.7m228.6m610.9m18.5m(14.4m)628.6m

Net Change in Cash

151.4m21.3m100.4m5.8m37.5m(12.9m)(20.5m)91.0m(17.9m)(22.4m)(7.7m)(4.2m)74.7m83.5m(14.1m)112.0m95.1m31.6m(33.4m)361.6m(164.7m)(129.6m)145.9m

Interest Paid

282.5k365.6k1.0k1.0k1.0k2.3m2.3m4.5m2.3m2.5m5.5m3.0m3.8m6.9m3.1m3.1m7.0m4.9m5.3m9.8m

Income Taxes Paid

225.0k264.0k633.0k28.0k334.0k616.0k326.0k758.0k919.0k537.0k1.0m1.9m507.0k1.1m1.6m

PTC Therapeutics Ratios

USDQ2, 2013

Financial Leverage

1.1 x

PTC Therapeutics Employee Rating

481 votes
Culture & Values
3.1
Work/Life Balance
2.7
Senior Management
2.7
Salary & Benefits
3.9
Career Opportunities
3
Source
View PTC Therapeutics profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more